Skip to main content
OpenTrials

Clinical trial condition

Thyroid Cancer, Papillary

Explore clinical trials studying Thyroid Cancer, Papillary. Study availability and eligibility vary by location and protocol.

138 public trials 26 recruiting studies
Refine in advanced search Browse all conditions

Thyroid Cancer, Papillary trial results

Completed

Study of XL281 in Adults With Solid Tumors

NCT00451880

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Neoplasms, +40 more
Locations
  • Premiere Oncology of Arizona Scottsdale, Arizona, United States
  • H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Active, Not Recruiting

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Brain Diseases, +59 more
Locations
  • University of California San Diego La Jolla, California, United States
  • UCSF Benioff Children's Hospital San Francisco, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Egleston Children's Hospital at Emory University Atlanta Atlanta, Georgia, United States
View all 26 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

NCT03914300

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +20 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • USC Norris Oncology/Hematology-Newport Beach Newport Beach, California, United States
View all 33 locations
View Trial Details
Active, Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +91 more
Locations
  • Dignity Health St Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Cancer Center Duarte, California, United States
  • City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services Duarte, California, United States
View all 130 locations
View Trial Details
Active, Not Recruiting

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

NCT01398085

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +13 more
Locations
  • Belfast Health and Social Care Trust Belfast, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom
  • University Hospitals Sussex NHS Foundation Trust Brighton, United Kingdom
  • University Hospital Bristol NHS Foundation Trust Bristol, United Kingdom
View all 36 locations
View Trial Details
Active, Not Recruiting

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Any Solid Tumor, +46 more
Locations
  • Mayo Clinic of Scottsdale Scottsdale, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • UCLA Medical Center Los Angeles, California, United States
  • Hoag Memorial Hospital Presbyterian Newport Beach, California, United States
View all 85 locations
View Trial Details

Related conditions